Exact Sciences Corp (NASDAQ: EXAS) on Friday, soared 1.26% from the previous trading day, before settling in for the closing price of $68.93. Within the past 52 weeks, EXAS’s price has moved between $40.62 and $79.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 43.88%. The company achieved an average annual earnings per share of 17.63%. With a float of $181.98 million, this company’s outstanding shares have now reached $184.77 million.
The extent of productivity of a business whose workforce counts for 6600 workers is very important to gauge. In terms of profitability, gross margin is 72.3%, operating margin of -7.26%, and the pretax margin is -6.59%.
Exact Sciences Corp (EXAS) Insider and Institutional Ownership
Observing investor behavior towards Diagnostics & Research industry stocks is more important than anything else. The insider ownership of Exact Sciences Corp is 1.51%, while institutional ownership is 97.58%. The most recent insider transaction that took place on Oct 08 ’24, was worth 65,030. In this transaction EVP, GM, Precision Oncology of this company sold 929 shares at a rate of $70.00, taking the stock ownership to the 12,758 shares. Before that another transaction happened on Oct 08 ’24, when Company’s Officer proposed sale 929 for $70.00, making the entire transaction worth $65,030.
Exact Sciences Corp (EXAS) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 17.63% per share during the next fiscal year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Exact Sciences Corp (EXAS) is currently performing well based on its current performance indicators. A quick ratio of 1.98 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.96, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach 0.14 in one year’s time.
Technical Analysis of Exact Sciences Corp (EXAS)
The latest stats from [Exact Sciences Corp, EXAS] show that its last 5-days average volume of 1.59 million was inferior to 2.52 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 43.41%. Additionally, its Average True Range was 2.24.
During the past 100 days, Exact Sciences Corp’s (EXAS) raw stochastic average was set at 93.02%, which indicates a significant increase from 50.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 28.94% in the past 14 days, which was lower than the 56.46% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $66.77, while its 200-day Moving Average is $58.87. Now, the first resistance to watch is $70.78. This is followed by the second major resistance level at $71.77. The third major resistance level sits at $73.37. If the price goes on to break the first support level at $68.19, it is likely to go to the next support level at $66.59. The third support level lies at $65.60 if the price breaches the second support level.
Exact Sciences Corp (NASDAQ: EXAS) Key Stats
Market capitalization of the company is 13.06 billion based on 184,770K outstanding shares. Right now, sales total 2,500 M and income totals -204,150 K. The company made 699,260 K in profit during its latest quarter, and -15,810 K in sales during its previous quarter.
